Novartis AG (NVSEF) Operating cash flow 2016–2025
Novartis AG (NVSEF) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$19.1BFY2025 · since FY2016: $11.5B → $19.1B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $19.1B | +8.7% |
| FY2024 | $17.6B | +21.9% |
| FY2023 | $14.5B | +1.6% |
| FY2022 | $14.2B | -5.5% |
| FY2021 | $15.1B | +10.4% |
| FY2020 | $13.7B | +0.2% |
| FY2019 | $13.6B | -4.5% |
| FY2018 | $14.3B | +13.1% |
| FY2017 | $12.6B | +10.0% |
| FY2016 | $11.5B | — |
Source: SEC XBRL filings · For reference only · Not investment advice